Placeholder

Vanlev: Coming Soon

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1764. Categories: , .

Product Description

In a second go-round for a drug that once was predicted to become a high flier, Bristol-Myers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, Bristol-Myers Squibb was set to seek approval for Vanlev, but withdrew the NDA because of a potentially life-threatening side effect.   Analysts, who had once predicted blockbuster status for Vanlev, now are cautiously optimistic about the drug’s chances and market potential based on newly conducted studies.
Upon approval, the novel vasopeptidase inhibitor Vanlev (omapatrilat) will enter an antihypertensive market, which is expected to reach $38.5 billion by 2003, according to a study by Front Line Strategic Consulting Inc. Vanlev is expected to take market share away from Merck, Pfizer, and Novartis, with sales close to $2.5 billion by 2006.
In mid-December 2001, Bristol-Myers Squibb resubmitted a new drug application (NDA) with the U.S. Food and Drug Administration for Vanlev for the treatment…

Sidebar:
A New Chapter in Novel Compounds
Bristol-Myers Squibb — Getting Back on Track

Experts on this topic
Henry Black, M.D. Associate VP for research, associate dean for research, Charles J. and Margaret Roberts Professor, and chairman Department of Preventive Medicine Rush-Presbyterian-St. Luke’s Medical Center, Chicago; the Department of Preventive Medicine focuses on primary and secondary disease prevention, particularly in the areas of hypertension, cardiovascular disease, and minority health
Nicola Maidwell, Ph.D. Research analyst, Decision Resources Inc., Waltham, Mass.; Decision Resources is a world leader in pharmaceutical and healthcare advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets
Herman Saftlas. Equity analyst, Health Care (Diversified), S&P Equity Group, New York; Standard & Poor’s, a division of The McGraw-Hill Companies, provides independent financial information, analytical services, and credit ratings
Dr. Michael Weber. Professor of medicine and associate dean for research, SUNY Downstate College of Medicine, Brooklyn, N.Y.; SUNY Downstate Medical Center is an academic medical center
Tracy Yeo, Ph.D. Associate, Front Line Strategic Consulting Inc., Foster City, Calif.; Front Line is a strategy and market consultancy
Joseph Zammit-Lucia. President of Cambridge Pharma Consultancy Ltd., Cambridge, England; Cambridge Pharma is a management consultancy providing high-quality advice to pharmaceutical and healthcare businesses
Nancy Zhang, Ph.D. Managing consultant, Front Line Strategic Consulting Inc., Foster City, Calif.; Front Line is a strategy and market consultancy

FEEDBACK